KT
PCRX icon

Kanaly Trust’s Pacira BioSciences PCRX Stock Holding History

Kanaly Trust’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2K Sell
65
-42
-39% -$1.4K ﹤0.01% 821
2016
Q3 		$4K Buy
+107
New +$4.19K ﹤0.01% 682

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kanaly Trust's PCRX Position: Q4 2016 in Review

Kanaly Trust reduced its Pacira BioSciences (PCRX) stake by 39% in Q4 2016, selling an estimated $1.4K and leaving 65 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #821.

Kanaly Trust first reported a position in PCRX in Q3 2016 and has held it in 2 quarters since. The position peaked at $4K in Q3 2016. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

  • Kanaly Trust held 65 shares of Pacira BioSciences worth $2K as of Q4 2016.
  • Kanaly Trust sold 42 Pacira BioSciences shares in Q4 2016, an estimated $1.4K.
  • Pacira BioSciences made up ﹤0.01% of Kanaly Trust's portfolio in Q4 2016, its #821 holding.
  • Kanaly Trust first reported a position in Pacira BioSciences in Q3 2016 and has held it in 2 quarters since.
  • Kanaly Trust's Pacira BioSciences position peaked at $4K in Q3 2016.
  • 182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on Kanaly Trust's 13F filing for Q4 2016, filed 23 Jan 2017.